2-Pyridone Derivatives Inhibit Neutrophil Elastase to Prevent Tissue Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human neutrophil elastase (hNE) imbalances contribute to various inflammatory diseases by causing uncontrolled tissue destruction, particularly in conditions like chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and emphysema, due to the lack of its endogenous inhibitor, α1-antitrypsin, leading to excessive tissue degradation and inflammation.
Innovation Solution
Development of 2-pyridone derivatives that act as human neutrophil elastase inhibitors, specifically compounds of formula (I) with defined structural features, which can be used to modulate serine protease activity and reduce tissue damage in inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human neutrophil elastase is present in high concentrations in neutrophils, then the enzyme can effectively degrade foreign organic molecules during phagocytosis, but uncontrolled release of NE into extracellular space causes excessive tissue degradation and inflammation
Solution Approach 1:
The patent introduces synthetic elastase inhibitors as intermediary substances that selectively bind to and inhibit neutrophil elastase. These inhibitors act as mediators between the beneficial intracellular phagocytic function and the harmful extracellular tissue degradation, allowing controlled modulation of NE activity to prevent tissue damage while preserving immune function.
Solution Approach 2:
The patent employs small molecule compounds that alter the enzymatic activity parameter of neutrophil elastase through competitive inhibition at the active site. By changing the kinetic parameters of the enzyme-inhibitor complex, the therapy reduces uncontrolled proteolytic activity while maintaining sufficient enzyme function for normal physiological processes.
2Object-affected harmful factors
If endogenous inhibitor α1-antitrypsin levels are insufficient, then neutrophil elastase activity remains uncontrolled causing tissue destruction, but increasing antitrypsin levels may not be feasible due to genetic or functional deficiencies
Solution Approach 1:
The patent employs small molecule inhibitor compounds that can be administered repeatedly as short-acting therapeutic agents. These disposable molecular inhibitors provide temporary but effective NE inhibition that can be replenished through regular dosing, offering a practical alternative to correcting underlying genetic deficiencies in α1-antitrypsin production.
Solution Approach 2:
The synthetic inhibitors described in the patent function as artificial copies or substitutes for the natural α1-antitrypsin inhibitor mechanism. Rather than attempting to correct the underlying deficiency in endogenous antiprotease production, the therapy replicates the inhibitory function using structurally simpler small molecules that can be manufactured and administered more easily.
3Productivity
If neutrophil elastase degrades extracellular matrix proteins such as elastin and collagens, then the enzyme fulfills its role in breaking down foreign materials, but this same capability causes emphysematous changes and lung structure destruction
Solution Approach 1:
The patent applies partial inhibition of neutrophil elastase activity through competitive inhibitors that occupy a portion of the enzyme molecules. This partial action approach allows sufficient proteolytic activity to maintain immune defense functions while reducing the excessive degradation that leads to emphysematous changes and structural lung damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 2-pyridone derivatives effectively inhibit human neutrophil elastase, potentially reducing tissue destruction and inflammation in diseases such as COPD, pulmonary fibrosis, and other inflammatory conditions, offering a therapeutic benefit by balancing NE activity.
Implementation Method 1
2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
Data Source
AI summary
The invention provides compounds of formula (1) wherein R1, R3, R4, R5, R6, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.